Johnson & Johnson and GlaxoSmithKline are leading research into new antibiotics - but a new report ... accessible and used wisely if they reach market. Nearly half of companies are helping to ...

The antibiotics market generated sales of US$42 billion ... retapamulin (Altabax; GlaxoSmithKline), a pleuromutilin approved in 2008; and tigecycline (Tygacil; Pfizer), a next-generation ...

GSK’s current market share is around 9% with a nice gap separating ... Two therapeutic areas that sell big in Egypt are antibiotics and NSAIDs. Four of the top 5 selling products of GSK are ...

However, inflation is likely to ease through 2025, which could lead to bigger interest rate cuts than the market expects ... respiratory diseases, and antibiotics. GSK plc (NYSE:GSK), with ...

The U.S. leads the antibiotic drugs market with 12.1% share, driven by rising infections, antibiotic demand, and robust government initiatives. NEWARK, DE, UNITED STATES, December 27, 2024 ...

Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is ...